| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 2,331.44 | 2,166.72 | 2,007.2 | 1,928.26 | 1,988.39 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,331.44 | 2,166.72 | 2,007.2 | 1,928.26 | 1,988.39 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 49.79 | 30.95 | 24.44 | 46.75 | 17.47 |
Total Income | 2,381.23 | 2,197.67 | 2,031.64 | 1,975.01 | 2,005.86 |
Total Expenditure | 1,775.11 | 1,676.05 | 1,625.3 | 1,553.14 | 1,613.33 |
PBIDT | 606.12 | 521.62 | 406.34 | 421.87 | 392.53 |
Interest | 74.88 | 69.57 | 67.56 | 45.15 | 36.43 |
PBDT | 531.24 | 452.05 | 338.78 | 376.72 | 356.1 |
Depreciation | 105.84 | 101.48 | 102.23 | 97.33 | 95.05 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 96.58 | 83.79 | 48.53 | 25.09 | 67.97 |
Deferred Tax | 0 | 0 | 0 | 0 | 0 |
Reported Profit After Tax | 328.82 | 266.78 | 188.02 | 254.3 | 193.08 |
Minority Interest After NP | 6.9 | 6.5 | 4.13 | 6.4 | 16.62 |
Net Profit after Minority Interest | 321.92 | 260.28 | 183.89 | 247.9 | 176.46 |
Extra-ordinary Items | 18.19 | 9.61 | -42.58 | 21.66 | -44.21 |
Adjusted Profit After Extra-ordinary item | 303.73 | 250.67 | 226.47 | 226.24 | 220.67 |
EPS (Unit Curr.) | 4.26 | 3.45 | 2.44 | 3.28 | 2.34 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 754.96 | 754.96 | 754.96 | 754.96 | 754.96 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 25.99 | 24.07 | 20.24 | 21.87 | 19.74 |
PBDTM(%) | 22.78 | 20.86 | 16.87 | 19.53 | 17.9 |
PATM(%) | 14.1 | 12.31 | 9.36 | 13.18 | 9.71 |
Fortis will take charge of the entire operational and financial aspects. Hence, consolidating the hospital's performance within its network.
Operating performance remained strong with EBITDA rising 43% year-on-year to ₹490.4 crore. The EBITDA margin expanded to 22.6%, from 18.4% a year ago.
The tax demand will not affect the company’s financials or operations, it said in a regulatory filing.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, Jio Financial, Avenue Supermarts, etc.
EBITDA grew 32.1% YoY at ₹375.2 crore v/s ₹284 crore, a period to period, as was the expansion of EBITDA margin at 19.5% versus 16.9% Q3 FY24.
The deal worth ₹429.37 crore involves acquiring 5,970,149 equity shares at an agreed price of ₹719.2 per share through a shareholders' agreement.
Revenue from operations saw a notable growth of 12.3%, reaching ₹1,988.4 Crore, compared to ₹1,770 Crore YoY.
Jacob Ballas and International Finance Corporation (IFC), who together with Resurgence PE own approximately 34% of the diagnostics company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
